Niroo Gupta

3.7k total citations · 2 hit papers
18 papers, 2.8k citations indexed

About

Niroo Gupta is a scholar working on Physiology, Immunology and Allergy and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Niroo Gupta has authored 18 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Physiology, 10 papers in Immunology and Allergy and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Niroo Gupta's work include Asthma and respiratory diseases (12 papers), Allergic Rhinitis and Sensitization (10 papers) and Food Allergy and Anaphylaxis Research (7 papers). Niroo Gupta is often cited by papers focused on Asthma and respiratory diseases (12 papers), Allergic Rhinitis and Sensitization (10 papers) and Food Allergy and Anaphylaxis Research (7 papers). Niroo Gupta collaborates with scholars based in United States, Switzerland and Germany. Niroo Gupta's co-authors include Angel FowlerTaylor, Giovanni Della Cioppa, Jonathan Corren, Bobby Q. Lanier, William W. Busse, Andre van As, Robert G. Townley, Jonathan Matz, J. Thirlwell and M. Solèr and has published in prestigious journals such as Journal of Clinical Investigation, PEDIATRICS and Radiology.

In The Last Decade

Niroo Gupta

17 papers receiving 2.7k citations

Hit Papers

Omalizumab, anti-IgE recombinant humanized monoclonal ant... 2001 2026 2009 2017 2001 2001 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
    2001 978 citations William W. Busse, Jonathan Corren et al. Journal of Allergy and Clinical Immunology profile →
  2. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics
    2001 647 citations M. Solèr, Jonathan Matz et al. European Respiratory Journal profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Niroo Gupta United States 13 2.5k 1.7k 1.4k 433 241 18 2.8k
Magnus Aurivillius Sweden 17 2.5k 1.0× 2.3k 1.3× 538 0.4× 553 1.3× 122 0.5× 57 3.3k
Eric Bradford United States 23 1.9k 0.7× 1.6k 0.9× 375 0.3× 421 1.0× 115 0.5× 59 2.3k
Εleftherios Ζervas Greece 19 827 0.3× 643 0.4× 193 0.1× 324 0.7× 31 0.1× 50 1.3k
C.T. Leonard United Kingdom 18 370 0.1× 694 0.4× 63 0.0× 227 0.5× 26 0.1× 51 1.2k
Nami Shrestha Palikhe South Korea 19 345 0.1× 148 0.1× 88 0.1× 189 0.4× 48 0.2× 39 689
Do-Jin Kim South Korea 18 252 0.1× 443 0.3× 45 0.0× 162 0.4× 88 0.4× 50 909
Katayoon Goodarzi United States 12 217 0.1× 154 0.1× 110 0.1× 294 0.7× 13 0.1× 27 1.6k
D. Yin United States 15 497 0.2× 362 0.2× 218 0.2× 56 0.1× 39 0.2× 24 1.3k
Victor E. Ortega United States 14 447 0.2× 367 0.2× 48 0.0× 104 0.2× 59 0.2× 49 820
Anca Mirela Chiriac France 19 259 0.1× 108 0.1× 586 0.4× 106 0.2× 107 0.4× 56 1.2k

Countries citing papers authored by Niroo Gupta

Since Specialization
Citations

This map shows the geographic impact of Niroo Gupta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Niroo Gupta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Niroo Gupta more than expected).

Fields of papers citing papers by Niroo Gupta

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Niroo Gupta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Niroo Gupta. The network helps show where Niroo Gupta may publish in the future.

Co-authorship network of co-authors of Niroo Gupta

This figure shows the co-authorship network connecting the top 25 collaborators of Niroo Gupta. A scholar is included among the top collaborators of Niroo Gupta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Niroo Gupta. Niroo Gupta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Casale, Thomas B., John J. Condemi, Craig LaForce, et al.. (2017). Effect of Omalizumab on Symptoms of Seasonal Allergic Rhinitis.
2.
Corren, Jonathan, et al.. (2005). Omalizumab is well tolerated in adolescent/adult patients (≥12 Years) with moderate-to-severe persistent asthma. Journal of Allergy and Clinical Immunology. 115(2). S75–S75. 12 indexed citations
3.
Deniz, Yamo & Niroo Gupta. (2005). Safety and Tolerability of Omalizumab (Xolair<SUP>®</SUP>), a Recombinant Humanized Monoclonal Anti-IgE Antibody. Clinical Reviews in Allergy & Immunology. 29(1). 31–48. 45 indexed citations
4.
Silkoff, Philip E., F.A. Romero, Niroo Gupta, Robert G. Townley, & Henry Milgrom. (2004). Exhaled Nitric Oxide in Children With Asthma Receiving Xolair (Omalizumab), a Monoclonal Anti-Immunoglobulin E Antibody. PEDIATRICS. 113(4). e308–e312. 69 indexed citations
5.
Nayak, Anjuli, Thomas B. Casale, S. David Miller, et al.. (2004). Tolerability of retreatment with omalizumab, a recombinant humanized monoclonal anti-IgE antibody, during a second ragweed pollen season in patients with seasonal allergic rhinitis.. PubMed. 24(5). 323–9. 32 indexed citations
6.
Berger, William E., et al.. (2003). Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma. Annals of Allergy Asthma & Immunology. 91(2). 182–188. 134 indexed citations
7.
Finn, Albert F., Gary N. Gross, Julius van Bavel, et al.. (2003). Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. Journal of Allergy and Clinical Immunology. 111(2). 278–284. 140 indexed citations
8.
Lanier, Bobby Q., Jonathan Corren, William R. Lumry, et al.. (2003). Omalizumab is effective in the long-term control of severe allergic asthma. Annals of Allergy Asthma & Immunology. 91(2). 154–159. 149 indexed citations
9.
Lemanske, Robert F., et al.. (2002). Omalizumab Improves Asthma-Related Quality of Life in Children With Allergic Asthma. PEDIATRICS. 110(5). e55–e55. 115 indexed citations
10.
Busse, William W., Jonathan Corren, Bobby Q. Lanier, et al.. (2001). Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. Journal of Allergy and Clinical Immunology. 108(2). 184–190. 978 indexed citations breakdown →
11.
Solèr, M., Jonathan Matz, Robert G. Townley, et al.. (2001). The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. European Respiratory Journal. 18(2). 254–261. 647 indexed citations breakdown →
12.
Milgrom, Henry, William Berger, Anjuli Nayak, et al.. (2001). Treatment of Childhood Asthma With Anti-Immunoglobulin E Antibody (Omalizumab). PEDIATRICS. 108(2). e36–e36. 382 indexed citations
13.
McKeever, Clark, et al.. (2000). An estradiol matrix transdermal system for the prevention of postmenopausal bone loss. Clinical Therapeutics. 22(7). 845–857. 8 indexed citations
14.
Cohen, Louis, et al.. (1999). Low-dose 17-beta estradiol matrix transdermal system in the treatment of moderate-to-severe hot flushes in postmenopausal women. Current Therapeutic Research. 60(10). 534–547. 5 indexed citations
15.
Alavi, Abass, Harold I. Palevsky, Niroo Gupta, et al.. (1990). Radiolabeled antifibrin antibody in the detection of venous thrombosis: preliminary results.. Radiology. 175(1). 79–85. 32 indexed citations
16.
Furst, Daniel E., Niroo Gupta, & Harold E. Paulus. (1977). Salicylate Metabolism in Twins. Journal of Clinical Investigation. 60(1). 32–42. 54 indexed citations
17.
Furst, Daniel E., et al.. (1976). Effects of salicylate on liver enzymes in normal young adults. Arthritis & Rheumatism. 19(2). 267–268. 4 indexed citations
18.
Gupta, Niroo, et al.. (1975). Correlation of plateau serum salicylate level with rate of salicylate metabolism. Clinical Pharmacology & Therapeutics. 18(3). 350–355. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Magnus Aurivillius Breakdown of academic impact, for papers by Eric Bradford Breakdown of academic impact, for papers by Εleftherios Ζervas Breakdown of academic impact, for papers by C.T. Leonard Breakdown of academic impact, for papers by Nami Shrestha Palikhe Breakdown of academic impact, for papers by Do-Jin Kim Breakdown of academic impact, for papers by Katayoon Goodarzi Breakdown of academic impact, for papers by D. Yin Breakdown of academic impact, for papers by Victor E. Ortega Breakdown of academic impact, for papers by Anca Mirela Chiriac
Rankless by CCL
2026